108 related articles for article (PubMed ID: 8423547)
1. Protective effect of E3330, a novel quinone derivative, in galactosamine-induced hepatitis in rats.
Nagakawa J; Hirota K; Hishinuma I; Miyamoto K; Sonoda J; Yamanaka T; Katayama K; Yamatsu I
J Pharmacol Exp Ther; 1993 Jan; 264(1):496-500. PubMed ID: 8423547
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of (2E)-3-[5-(2,3-dimethoxy-6-methyl-1,4- benzoquinoyl)]-2-nonyl-2-propenoic acid on endotoxin-mediated hepatitis in mice.
Nagakawa J; Hishinuma I; Miyamoto K; Hirota K; Abe S; Yamanaka T; Katayama K; Yamatsu I
J Pharmacol Exp Ther; 1992 Jul; 262(1):145-50. PubMed ID: 1625194
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of E3330, a novel quinone derivative, on galactosamine/tumor necrosis factor-alpha-induced hepatitis in mice.
Nagakawa J; Hishinuma I; Hirota K; Miyamoto K; Yamanaka T; Yamatsu I; Katayama K
Eur J Pharmacol; 1992 Dec; 229(1):63-7. PubMed ID: 1335420
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of a novel quinone derivative, (2E)-3-[5-(2,3 dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propanoic acid on experimental alcoholic liver injury.
Nanji AA; Sadrzadeh SM; Khettry U; Thomas P; Yamanaka T
J Pharmacol Exp Ther; 1993 Aug; 266(2):1085-90. PubMed ID: 8394904
[TBL] [Abstract][Full Text] [Related]
5. Suppressive effects of E3330, a novel quinone derivative, on tumor necrosis factor-alpha generation from monocytes and macrophages.
Miyamoto K; Nagakawa J; Hishinuma I; Hirota K; Yasuda M; Yamanaka T; Katayama K; Yamatsu I
Agents Actions; 1992 Nov; 37(3-4):297-304. PubMed ID: 1284192
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of glucocorticoid-mediated gene expression by the novel benzoquinone derivative (2E)-3-[5-(2,3-dimethoxy-o-methyl-1, 4-benzoquinoyl)]-2-nonyl-2-propenoic acid (E3330).
Tanaka H; Makino Y; Hiramoto M; Handa H; Makino I
Eur J Pharmacol; 1995 Oct; 291(2):121-7. PubMed ID: 8566161
[TBL] [Abstract][Full Text] [Related]
7. A novel biologically active seleno-organic compound--VI. Protection by ebselen (PZ 51) against galactosamine/endotoxin-induced hepatitis in mice.
Wendel A; Tiegs G
Biochem Pharmacol; 1986 Jul; 35(13):2115-8. PubMed ID: 3729968
[TBL] [Abstract][Full Text] [Related]
8. Increased sinusoidal efflux of reduced and oxidized glutathione in rats with endotoxin/D-galactosamine hepatitis.
Irita K; Okabe H; Koga A; Kurosawa K; Tagawa K; Yamakawa M; Yoshitake J; Takahashi S
Circ Shock; 1994 Mar; 42(3):115-20. PubMed ID: 8025975
[TBL] [Abstract][Full Text] [Related]
9. Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis.
Masubuchi Y; Horie T
Drug Metab Dispos; 2004 Apr; 32(4):437-41. PubMed ID: 15039297
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B.
Goto M; Yamada K; Katayama K; Tanaka I
Mol Pharmacol; 1996 May; 49(5):860-73. PubMed ID: 8622636
[TBL] [Abstract][Full Text] [Related]
11. Protection by ebselen against endotoxin shock in rats or mice sensitized by galactosamine.
Konz KH; Tiegs G; Wendel A
Prog Clin Biol Res; 1987; 236A():281-8. PubMed ID: 3615436
[TBL] [Abstract][Full Text] [Related]
12. Significance of endotoxaemia in experimental "galactosamine-hepatitis" in the rat.
Grün M; Liehr H; Rasenack U
Acta Hepatogastroenterol (Stuttg); 1977 Apr; 24(2):64-81. PubMed ID: 857560
[TBL] [Abstract][Full Text] [Related]
13. [Endotoxin-inactivating activity in normal and D-galactosamine induced liver failure rats].
Taki S; Nakao A
Nihon Geka Gakkai Zasshi; 1993 Dec; 94(12):1256-62. PubMed ID: 8272064
[TBL] [Abstract][Full Text] [Related]
14. Leukotriene-mediated liver injury.
Tiegs G; Wendel A
Biochem Pharmacol; 1988 Jul; 37(13):2569-73. PubMed ID: 2839197
[TBL] [Abstract][Full Text] [Related]
15. Treatment of endotoxemia in galactosamine hepatitis by lactulose administered intravenously.
Liehr H; Heine WD
Hepatogastroenterology; 1981 Dec; 28(6):296-8. PubMed ID: 7345010
[No Abstract] [Full Text] [Related]
16. Hepatoprotective effect of allicin on tissue defense system in galactosamine/endotoxin challenged rats.
Vimal V; Devaki T
J Ethnopharmacol; 2004 Jan; 90(1):151-4. PubMed ID: 14698523
[TBL] [Abstract][Full Text] [Related]
17. Increase in the plasma concentration of reduced glutathione observed in rats with liver damage induced by lipopolysaccharide/D-galactosamine: effects of ulinastatin, a urinary trypsin inhibitor.
Okabe H; Irita K; Kurosawa K; Tagawa K; Koga A; Yamakawa M; Yoshitake J; Takahashi S
Circ Shock; 1993 Dec; 41(4):268-72. PubMed ID: 8143354
[TBL] [Abstract][Full Text] [Related]
18. The effect of endotoxin and Lactobacillus pretreatment on peritoneal macrophage behavior in acute liver injury in rat.
Kasravi FB; Gebreselassie D; Adawi D; Wang L; Molin G; Bengmark S; Jeppsson B
J Surg Res; 1996 Apr; 62(1):63-8. PubMed ID: 8606512
[TBL] [Abstract][Full Text] [Related]
19. [Protective and curative effects of diethyldithiocarbamate on galactosamine hepatitis in the rat (author's transl)].
Homann J; Gerhardt H; Hopf F
Arzneimittelforschung; 1980; 30(4):645-7. PubMed ID: 6249330
[TBL] [Abstract][Full Text] [Related]
20. The effect of pretreatment with endotoxin and lactobacillus on bacterial translocation in acute liver injury.
Kasravi FB; Adawi D; Hägerstrand I; Molin G; Bengmark S; Jeppsson B
Eur J Surg; 1996 Jul; 162(7):537-44. PubMed ID: 8874160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
